Here are the DEF 14A proxy statements from Kalaris Therapeutics, Inc. (KLRS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow KLRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRS filings page.
Kalaris Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 3, 2026 at 11:30 a.m. Eastern. Proposals include electing three Class III directors, an advisory say-on-pay vote, an advisory vote on say-on-pay frequency, and ratifying Deloitte & Touche LLP as auditor.
The record date is April 6, 2026, with about 11,496,146 common shares outstanding for quorum. Kalaris is classified as a “smaller reporting company” and a “controlled company,” allowing scaled disclosures and some exemptions from Nasdaq independence requirements. The meeting will be held exclusively online via www.proxydocs.com/KLRS.